1196156-90-7

Basic information

• Product Name: 2-(ChloroMethyl)-5-Methoxypyrazine
• Synonyms: 2-(ChloroMethyl)-5-Methoxypyrazine;RDZSXLXGRSWNAQ-UHFFFAOYSA-N
• CAS NO: 1196156-90-7
• Molecular Formula: C6H7ClN2O
• Molecular Weight: 158.58558
• Mol File: 1196156-90-7.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 229.1±35.0℃ (760 Torr)
• Flash Point: 92.4±25.9℃
• Appearance: /
• Density: 1.243±0.06 g/cm3 (20 ºC 760 Torr)
• CAS DataBase Reference: 2-(ChloroMethyl)-5-Methoxypyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(ChloroMethyl)-5-Methoxypyrazine(1196156-90-7)
• EPA Substance Registry System: 2-(ChloroMethyl)-5-Methoxypyrazine(1196156-90-7)

Safety Data

• Hazardous Substances Data: 1196156-90-7(Hazardous Substances Data)

Usage

General Description

2-(ChloroMethyl)-5-Methoxypyrazine is a chemical compound with the molecular formula C7H8ClN3O. It is a pale yellow liquid with a molecular weight of 183.61 g/mol. This chemical is commonly used in the fragrance industry as it has a strong, earthy, and green odor reminiscent of tomato vines. It is also used as a flavoring agent in the food industry, adding a unique, herbaceous note to various products. Additionally, 2-(ChloroMethyl)-5-Methoxypyrazine has potential applications in the pharmaceutical industry due to its biological activity and ability to act as a precursor for the synthesis of other compounds with therapeutic properties. The chemical is considered to have low acute toxicity, but proper safety precautions should still be observed when handling and using it.

Upstream product

• 38789-75-2 methyl 5-methoxypyrazine-2-carboxylate 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 
• 72788-88-6 (5-methoxypyrazin-2-yl)methanol 

Relevant articles and documents

Novel indirect AMP-activated protein kinase activators: Identification of a second-generation clinical candidate with improved physicochemical properties and reduced hERG inhibitory activity

This study reports the synthesis and evaluation of novel indirect AMP-activated protein kinase (AMPK) activators. The series of compounds selectively inhibited cell growth in several human breast cancer cell lines by activating AMPK. We performed back-up medicinal chemistry synthetic research on ASP4132, a previously reported as a compound for clinical development that acts as an indirect AMPK activator. This led to the successful identification of 4-({4-[5-({1-[(5-ethoxypyrazin-2-yl)methyl]-4-fluoropiperidin-4-yl}methoxy)-3-methylpyridine-2-carbonyl]piperazin-1-yl}methyl)benzonitrile succinate (27b), a potent, highly aqueous soluble and metabolically stable compound in human hepatocytes. Compound 27b also showed weaker human Ether-a-go-go Related Gene (hERG) inhibitory activity than that of compound 13 and ASP4132. Therefore, 27b was a promising AMPK activator and a second-generation clinical candidate for treatment for human cancer.